CYTH News and Press, Cyclo Therapeutics Inc. From 09/27/21

- Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical development leaders...

- Live webcast presentation on Wednesday, September 22 nd at 10:45 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

- Solid clinical and operational execution demonstrated with advancement of Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with commencement of pivotal study (TransportNPC™) and start of commercial-scale manufacturing - Progression of Phase 2 ...

ERYTECH Pharma S.A. (NASDAQ:ERYP) +99%. Ardelyx (NASDAQ:ARDX) +14% on Q2 earnings Taoping  (NASDAQ:TAOP) +12% signs strategic cooperation agreement with Shenzhen IntelStrat Technology Co., Ltd Atlassian Corporation Plc (NASDAQ:TEAM) +12%. LM Funding America (NASDAQ:LMFA) +...

Cyclo Therapeutics (NASDAQ:CYTH) announces new data from its Phase 1 extension study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC), a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells. The Compa...

- Data seen to-date in the ongoing Phase 1 extension study provide additional support for the capacity of Trappsol ® Cyclo™ to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1 (“NPC”) - Favorable ...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Company to discuss clinical progress of Trappsol ® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical st...

The results of future clinical trials may have some slight bearing on Biogen's stock value. If several restrictions are put on the coverage of Biogen's Aduhelm, that would negatively impact the stock to some degree. Biogen's stock value would drop further if others in the Alzheime...

Cyclo Therapeutics (CYTH) jumps 10% premarket after commencing Phase 3 study (TransportNPC) evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of Niemann-Pick Disease Type C1 (NPC1), a rare ge...